4

PRIMARY DOCUMENT

Company: REGENERON PHARMACEUTICALS, INC.
Filed: August 25, 2023
Period of Report: August 23, 2023
Accession Number: 0001968202-23-000031

View Document ↗ View on SEC.gov ↗